Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.

Monge, SusanaHumphreys, JamesNicolay, NathalieBraeye, ToonVan Evercooren, IzaakHolm Hansen, ChristianEmborg, Hanne-DortheSacco, ChiaraMateo-Urdiales, AlbertoCastilla, JesúsMartínez-Baz, Ivánde Gier, BrechjeHahné, SusanMeijerink, HintaKristoffersen, Anja BråthenMachado, AusendaSoares, PatriciaNardone, AnthonyBacci, SabrinaKissling, EstherNunes, Baltazar2024-04-302024-04-302024-04-303865448510.1111/irv.13292http://hdl.handle.net/10029/627546en© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.COVID‐19SARS‐CoV‐2cohort designelectronic health recordshospitalisationmulticountry studyvaccine effectivenessEffectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.Article1750-2659Influenza Other Respir Viruses 2024;18(4):e13292